These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2016 Archives

Nov 22, 2016
Confirms plans for pivotal phase 3 Overall Survival study with Ceplene in AML
Nov 17, 2016
Oct 27, 2016
Oct 17, 2016
Maxim Pharmaceuticals to focus dedicated financial resources to AmiKet® late stage development
Sep 16, 2016
Sep 7, 2016
Aug 16, 2016
Jul 19, 2016
IMMUNE and NPT targets closing date of September 15, 2016.
Jun 28, 2016
Immune Pharmaceuticals Files New Provisional Patent Application
Jun 20, 2016
New Data Presented at the Conference "Regulatory Myeloid Suppressor Cells: From Basic Discovery to Therapeutic Application" Expands Knowledge of Ceplene® Mechanism of Action and Identifies Potential New Indications for Solid Tumors and Lymphoma
Jun 20, 2016
Jun 14, 2016
Jun 7, 2016
May 16, 2016
Apr 19, 2016
Previous Phase III Study Had Demonstrated Improvement of Over 130% in 3 Year Leukemia Free Survival in M4-M5 AML Subtype Patients Under 60 Years of Age
Mar 30, 2016
Mar 22, 2016
Focus on Development of New Drug Candidates targeting Immune Checkpoints
Mar 17, 2016
Overall Survival was Predicted by Re-Distribution of Cytotoxic T-Cell Subsets During Therapy with Ceplene in Patients with Acute Myeloid Leukemia
Feb 29, 2016
Feb 25, 2016
Feb 24, 2016
Feb 10, 2016
Feb 8, 2016
Feb 3, 2016
Jan 12, 2016
 

print email rss